RPL17 and neoplasm: This study presents nivolumab as a new PD-1 blockade antibody and is the first to evaluate its efficacy and safety in relapsed or refractory Hodgkin’s lymphoma, providing a crucial basis for subsequent clinical applications in combating tumor immune escape (21).